Rallybio Corp financial data

Symbol
RLYB on Nasdaq
Industry
Pharmaceutical Preparations
Location
234 Church Street, Suite 1020, New Haven, CT
State of incorporation
DE
Fiscal year end
December 31
Former names
Rallybio Holdings, LLC (to 6/7/2021)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 965 % -45.5%
Debt-to-equity 11.6 % +88.8%
Return On Equity -43.6 %
Return On Assets -69.3 % -53.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.5M shares +9.77%
Common Stock, Shares, Outstanding 41.5M shares +9.75%
Entity Public Float 134M USD +11.4%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 44.6M shares +10%
Weighted Average Number of Shares Outstanding, Diluted 44.6M shares +10%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 299K USD
Research and Development Expense 50M USD +3.37%
General and Administrative Expense 20.6M USD -22.4%
Operating Income (Loss) -70M USD +6.56%
Nonoperating Income (Expense) 5.45M USD -9.61%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -65.6M USD -44.1%
Net Income (Loss) Attributable to Parent -67M USD +5.04%
Earnings Per Share, Basic -1.6 USD/shares +10.1%
Earnings Per Share, Diluted -1.6 USD/shares +10.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.3M USD +32.2%
Marketable Securities, Current 49.8M USD -51.3%
Cash, Cash Equivalents, and Short-term Investments 75.1M USD -38.1%
Other Assets, Current 1.75M USD -51.3%
Assets, Current 78.2M USD -40.9%
Property, Plant and Equipment, Net 145K USD -48.6%
Operating Lease, Right-of-Use Asset 201K USD -48.2%
Assets 79M USD -40.7%
Accounts Payable, Current 583K USD +25.6%
Accrued Liabilities, Current 6.28M USD -28%
Contract with Customer, Liability, Current 1.1M USD
Liabilities, Current 8.19M USD -12.9%
Contract with Customer, Liability, Noncurrent 195K USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 8.19M USD -14.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 169K USD
Retained Earnings (Accumulated Deficit) -282M USD -31.2%
Stockholders' Equity Attributable to Parent 70.8M USD -42.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 169M USD -3.58%
Liabilities and Equity 79M USD -40.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.5M USD +17.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 10.3M USD +601%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 41.5M shares +9.75%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.19M USD +70.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.3M USD +32.2%
Deferred Tax Assets, Valuation Allowance 78.3M USD +55.9%
Deferred Tax Assets, Gross 78.3M USD +55.9%
Operating Lease, Liability 392K USD -29.4%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -66.6M USD +5.27%
Lessee, Operating Lease, Liability, to be Paid 406K USD -30.7%
Operating Lease, Liability, Current 230K USD +5.99%
Lessee, Operating Lease, Liability, to be Paid, Year Two 176K USD -23.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 230K USD +15%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14K USD -54.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 37.2M USD +40.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 156K USD
Additional Paid in Capital 353M USD +4.08%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 8.58M USD -19.6%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%